Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adcetris in Relapsed/Refractory CD30-positive NHL (BRAN)
NCT02280785Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Nov 2014
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in non-Hodgkin lymphoma (NHL), sponsored by Samsung Medical Center. Primary endpoint: Overall Disease Control Rate at 36 months. Started Nov 2014; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02280785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280785.